TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma

TransThera Sciences Inc. announced that the US FDA has granted Fast Track Designation to its Phase II stage product TT-00420 for the treatment of patients with Cholangiocarcinom who have no standard treatment options.